keyword
MENU ▼
Read by QxMD icon Read
search

BCG immunotherapy

keyword
https://www.readbyqxmd.com/read/28620382/phase-ii-study-of-adjuvant-immunotherapy-with-the-csf-470-vaccine-plus-bacillus-calmette-guerin-plus-recombinant-human-granulocyte-macrophage-colony-stimulating-factor-vs-medium-dose-interferon-alpha-2b-in-stages-iib-iic-and-iii-cutaneous-melanoma-patients
#1
José Mordoh, María Betina Pampena, Mariana Aris, Paula Alejandra Blanco, Mónica Lombardo, Erika María von Euw, Soledad Mac Keon, Michelle Yépez Crow, Alicia Inés Bravo, Juan Manuel O'Connor, Ana Gabriela Orlando, Franco Ramello, Estrella Mariel Levy, María Marcela Barrio
The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB-III cutaneous melanoma (CM) patients (pts) after surgery in an open, randomized, Phase II/III study. We present the results of the Phase II part of the ongoing CASVAC-0401 study (ClinicalTrials.gov: NCT01729663). Thirty-one pts were randomized to the CSF-470 vaccine (n = 20) or to the IFN-α2b arm (n = 11)...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28609792/-systematic-review-on-conservative-treatment-options-in-non-muscle-invasive-bladder-cancer-patients-refractory-to-bacillus-calmette-gu%C3%A3-rin-instillation-therapy
#2
Thomas Martini, Felix Wezel, Niklas Löbig, Michael J Mitterberger, Daniela Colleselli
Background Adjuvant Bacillus Calmette-Guérin (BCG) intravesical instillation is the recommended standard treatment in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, a significant proportion of patients fail treatment, and radical cystectomy (RC) is the subsequent gold standard. On the other hand, there is an unmet need for conservative alternatives for patients who are unfit or unwilling to undergo surgery. This study aimed to identify conservative treatment options in NMIBC patients after BCG failure...
June 13, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28601885/safety-and-efficacy-of-intravesical-bacillus-calmette-gu%C3%A3-rin-immunotherapy-in-patients-with-non-muscle-invasive-bladder-cancer-presenting-with-asymptomatic-bacteriuria-a-systematic-review
#3
Sławomir Poletajew, Piotr Zapała, Piotr Radziszewski
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU) remains a matter of debate. The aim of this systematic review was to present available evidence on the safety and efficacy of BCG immunotherapy in patients with ABU. A literature search within the Medline and the Embase databases was conducted with the following search terms: adverse events, bacteriuria, BCG, bladder cancer, cystitis, infection, pyuria, side effects and urinary tract infection (UTI)...
June 10, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28588015/intravesical-bcg-induces-cd4-t-cell-expansion-in-an-immune-competent-model-of-bladder-cancer
#4
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel, Leonardo O Reis, George J Netto, Mohammad Hoque, Noah M Hahn, David J McConkey, Alex S Baras, Charles G Drake, Trinity J Bivalacqua
Intravesical BCG immunotherapy is the standard of care in treating non-muscle invasive bladder cancer, yet its mechanism of action remains elusive.  Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4(+) T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized.  We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer...
June 6, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28583311/next-generation-sequencing-of-nonmuscle-invasive-bladder-cancer-reveals-potential-biomarkers-and-rational-therapeutic-targets
#5
Eugene J Pietzak, Aditya Bagrodia, Eugene K Cha, Esther N Drill, Gopa Iyer, Sumit Isharwal, Irina Ostrovnaya, Priscilla Baez, Qiang Li, Michael F Berger, Ahmet Zehir, Nikolaus Schultz, Jonathan E Rosenberg, Dean F Bajorin, Guido Dalbagni, Hikmat Al-Ahmadie, David B Solit, Bernard H Bochner
BACKGROUND: Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel therapeutic strategies. OBJECTIVE: To identify genetic alterations with potential clinical implications in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Pretreatment index tumors and matched germline DNA from 105 patients with NMIBC on a prospective Institutional Review Board-approved protocol underwent targeted exon sequencing analysis in a Clinical Laboratory Improvement Amendments-certified clinical laboratory...
June 2, 2017: European Urology
https://www.readbyqxmd.com/read/28507799/characterization-of-a-human-anti-tumoral-nk-cell-population-expanded-after-bcg-treatment-of-leukocytes
#6
Eva M García-Cuesta, Gloria Esteso, Omodele Ashiru, Sheila López-Cobo, Mario Álvarez-Maestro, Ana Linares, Mei M Ho, Luis Martínez-Piñeiro, Hugh T Reyburn, Mar Valés-Gómez
Immunotherapy, via intra-vesical instillations of BCG, is the therapy of choice for patients with high-risk non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as well as the release of cytokines and chemokines, is believed to induce a local immune response that eliminates these tumors, but the detailed mechanisms of action of this therapy are not well understood. Here, we have studied the phenotype and function of the responding lymphocyte populations as well as the spectrum of cytokines and chemokines produced in an in vitro model of human peripheral blood mononuclear cells (PBMCs) co-cultured with BCG...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#7
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
May 11, 2017: Drugs
https://www.readbyqxmd.com/read/28488840/bladder-cancer-and-th1-chemokines
#8
S-R Paparo, P Fallahi
Bladder cancer arises from the epithelial lining of the urinary bladder, and it is known as transitional cell carcinoma (TCC). Tobacco smoking is the main known contributor to urinary bladder cancer. However thirty percent of bladder tumors probably result from occupational exposure in the workplace to carcinogens. Immunotherapy by intravesicular delivery of Bacillus Calmette–Guérin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer. Successful BCG immunotherapy for bladder cancer is associated with proper induction of T helper (Th)1 immunity...
January 2017: La Clinica Terapeutica
https://www.readbyqxmd.com/read/28471272/determining-optimal-maintenance-schedules-for-adjuvant-intravesical-bacillus-calmette-guerin-immunotherapy-in-non-muscle-invasive-bladder-cancer-a-systematic-review-and-network-meta-analysis
#9
Zixiong Huang, Huixin Liu, Yizeng Wang, Chunfang Zhang, Tao Xu
OBJECTIVES: To figure out optimal bacillus Calmette-Guerin (BCG) maintenance schedules for non-muscle-invasive bladder cancer (NMIBC) patients by comparing different schedules in a systematic review using conventional and network meta-analysis. MATERIALS AND METHODS: Literature was searched in the databases of Medline, Embase, Cochrane library, Clinicaltrials.gov, Wanfang, CNKI and SinoMed in April 2016 and 9 randomized clinical trials comparing intravesical BCG maintenance therapy with BCG induction-only therapy or comparing different BCG maintenance schedules (induction-only, 1 year, 1...
June 6, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28469275/prognostic-value-of-impaired-estimated-glomerular-filtration-rate-in-intravesical-bcg-treated-non-muscle-invasive-bladder-cancer-patients
#10
Bum Sik Tae, Jung Kwon Kim, Minyong Kang, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy in patients with non-muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28467974/expression-of-sialyl-tn-sugar-antigen-in-bladder-cancer-cells-affects-response-to-bacillus-calmette-gu%C3%A3-rin-bcg-and-to-oxidative-damage
#11
Paulo F Severino, Mariana Silva, Mylene Carrascal, Nadia Malagolini, Mariella Chiricolo, Giulia Venturi, Annalisa Astolfi, Mariangela Catera, Paula A Videira, Fabio Dall'Olio
The sialyl-Tn (sTn) antigen is an O-linked carbohydrate chain aberrantly expressed in bladder cancer (BC), whose biosynthesis is mainly controlled by the sialyltransferase ST6GALNAC1. Treatment with Bacillus Calmette-Guérin (BCG) is the most effective adjuvant immunotherapy for superficial BC but one third of the patients fail to respond. A poorly understood correlation between the expression of sTn and BC patient's response to BCG was previously observed. By analyzing tumor tissues, we showed that patients with high ST6GALNAC1 and IL-6 mRNA expression were BCG responders...
April 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28406148/bladder-cancer
#12
REVIEW
Oner Sanli, Jakub Dobruch, Margaret A Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E Nielsen, Yair Lotan
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours...
April 13, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28389159/validation-of-the-ezrin-ck20-and-ki-67-as-potential-predictive-markers-for-bcg-instillation-therapy-of-non-muscle-invasive-bladder-cancer
#13
Per-Uno Malmström, Tammer Hemdan, Ulrika Segersten
OBJECTIVE: The aim of our study was to try to validate 3 promising predictive biomarkers in a database based on prospective trials comparing bacillus Calmette-Guerin (BCG) with mitomycin-C and a combination of epirubicin and interferon, respectively. BACKGROUND: The most common form of bladder cancer is non-muscle-invasive tumors treated initially with transurethral resection. Unfortunately more than half recur and some also progress. Consequently, an attempt to prevent poor outcome is frequently made by intravesical instillations either by chemo- or immunotherapy...
April 4, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28359179/tackling-non-muscle-invasive-bladder-cancer-in-the-clinic
#14
REVIEW
Solomon L Woldu, Öner Şanli, Yair Lotan
Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC - which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG)...
May 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28344356/methylation-status-as-a-predictor-of-intravesical-bacillus-calmette-gu%C3%A3-rin-bcg-immunotherapy-response-of-high-grade-non-muscle-invasive-bladder-tumor
#15
Petr Husek, Jaroslav Pacovsky, Marcela Chmelarova, Miroslav Podhola, Milos Brodak
BACKGROUND AND AIMS: Genetic and epigenetic alterations play an important role in urothelial cancer pathogenesis. Deeper understanding of these processes could help us achieve better diagnosis and management of this life-threatening disease. The aim of this research was to evaluate the methylation status of selected tumor suppressor genes for predicting BCG response in patients with high grade non-muscle-invasive bladder tumor (NMIBC). MATERIALS AND METHODS: We retrospectively evaluated 82 patients with high grade non-muscle-invasive bladder tumor (stage Ta, T1, CIS) who had undergone BCG instillation therapy...
March 22, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28278504/assessing-the-feasibility-of-replacing-standard-dose-bacillus-calmette-gu%C3%A3-rin-immunotherapy-with-other-intravesical-instillation-therapies-in-bladder-cancer-patients-a-network-meta-analysis
#16
Cheng Wu, Xunrong Zhou, Chunqing Miao, Jianzhong Zhang, Qingsheng Tang, Xiumei Chang, Haodong Ni
BACKGROUND: Bacillus Calmette-Guérin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives with equivalent efficacy If other alternative intravesical agents have equivalent efficacy compared to BCG, then it may be feasible to replace standard BCG with alternative options. METHODS: We searched all relevant evidence in multiple sources and key data was extracted from included studies...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28248951/bcg-unresponsive-non-muscle-invasive-bladder-cancer-recommendations-from-the-ibcg
#17
REVIEW
Ashish M Kamat, Marc Colombel, Debasish Sundi, Donald Lamm, Andreas Boehle, Maurizio Brausi, Roger Buckley, Raj Persad, Joan Palou, Mark Soloway, J Alfred Witjes
Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer...
April 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28197393/preclinical-efficacy-and-safety-of-the-ty21a-vaccine-strain-for-intravesical-immunotherapy-of-non-muscle-invasive-bladder-cancer
#18
Sonia Domingos-Pereira, Valérie Cesson, Mathieu F Chevalier, Laurent Derré, Patrice Jichlinski, Denise Nardelli-Haefliger
Intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy can reduce recurrence/progression of non-muscle-invasive bladder cancer (NMIBC), although significant adverse events and treatment failure argue for alternative options. Here, we examined whether another attenuated live vaccine, Vivotif/Ty21a, used since more than 30 y against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Mice-bearing MB49 orthotopic bladder-tumors treated with intravesical Ty21a or BCG were compared for survival and bacteria recovery...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28161459/peptide-microarray-based-characterization-of-antibody-responses-to-host-proteins-after-bacille-calmette-gu%C3%A3-rin-vaccination
#19
REVIEW
Davide Valentini, Martin Rao, Lalit Rane, Sayma Rahman, Rebecca Axelsson-Robertson, Rainer Heuchel, Matthias Löhr, Daniel Hoft, Susanna Brighenti, Alimuddin Zumla, Markus Maeurer
BACKGROUND: Bacille Calmette-Guérin (BCG) is the world's most widely distributed vaccine, used against tuberculosis (TB), in cancer immunotherapy, and in autoimmune diseases due to its immunomodulatory properties. To date, the effect of BCG vaccination on antibody responses to host proteins has not been reported. High-content peptide microarrays (HCPM) offer a unique opportunity to gauge specific humoral immune responses. METHODS: The sera of BCG-vaccinated healthy adults were tested on a human HCPM platform (4953 randomly selected epitopes of human proteins) to detect specific immunoglobulin gamma (IgG) responses...
February 2, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28134806/systemic-immunotherapy-for-urothelial-cancer-current-trends-and-future-directions
#20
REVIEW
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens...
January 27, 2017: Cancers
keyword
keyword
7100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"